ReviewCurrent rheumatology reports2010
Drug-related myopathies of which the clinician should be aware.
Review in Current rheumatology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- The Safety and Tolerability of Statin Therapy in Primary Prevention in Older Adults: A Systematic Review and Meta-analysis.Drugs & aging · 2020 · on this mapPooled it
- Rhabdomyolysis: a narrative review.Arquivos de neuro-psiquiatria · 2026Review
- Polymyxin B-Associated Muscle Injury: A Case Report.Infection and drug resistance · 2026Article
- Pharmacovigilance analysis of myopathy associated with azoles and nonstatins interactions based on US FAERS database.Scientific reports · 2025Article
- Reduced forearm muscle thickness and hand strength in patients with rheumatoid arthritis: an ultrasonographic cross-sectional study.Rheumatology international · 2025Article
- Article
- Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations.Dermatology and therapy · 2024Article
- Asymptomatic COVID-19 Infection-Induced Rhabdomyolysis in the Backdrop of Statin-Cyclosporine Drug Interaction.Cureus · 2024Article
- A 25-Year-Old Military Recruit with Isolated Myositis Following Routine Chemoprophylaxis with Intramuscular Benzathine Penicillin G.The American journal of case reports · 2024Article
- Intravesical bacillus Calmette-Guérin-induced myopathy presenting as rhabdomyolysis: a case report.Journal of Yeungnam medical science · 2023Article
- Is It Polymyositis?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2023Article
- Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment.Nephron · 2023Observational
- Identification of Agents That Ameliorate Hyperphosphatemia-Suppressed Myogenin Expression Involved in the Nrf2/p62 Pathway in C2C12 Skeletal Muscle Cells.International journal of molecular sciences · 2022Article
- Bilateral upper extremity myositis after COVID-19 vaccination.BJR case reports · 2022Article
- A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- A Case of Acute Necrotizing Myopathy in a Patient with Systemic Lupus Erythematosus.The American journal of case reports · 2022Article
- Azole-Induced Myositis after Combined Lung-Liver Transplantation.Case reports in transplantation · 2022Article
- Successful treatment of tuberculosis combined with drug-induced myopathy using corticosteroid therapy: a case report.The Journal of international medical research · 2021Article
- Ascorbic Acid Significantly Decreases Creatine Kinase Plasma Levels in an Animal Model of Statin/Fibrate-Induced Myopathy.Advances in pharmacological and pharmaceutical sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many drugs used for therapeutic interventions can cause unanticipated toxicity in muscle tissue, often leading to considerable morbidity. A drug-induced, or toxic, myopathy is defined as the acute or subacute manifestation of myopathic symptoms such as muscle weakness, myalgia, creatine kinase elevation, or myoglobinuria that can occur in patients without muscle disease when they are exposed to certain drugs. A brief review of agents with a known association with myotoxicity and the proposed mechanisms linked to that toxicity is outlined; however, the purpose of this review is to highlight recent discoveries and advances in the field of toxic myopathies that have practical implications for practicing physicians. Because many drug-related myopathies are potentially reversible at early stages, it is important for clinicians to recognize toxic myopathies early in their course to determine when to discontinue therapy and potentially prevent irreversible muscle damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.